It was revealed that plasma membrane expression of TRPV2 is enhanced and activated in cardiomyopathy, and TRPV2 inhibition decreases plasma membrane localization of TRPV2, abnormal Ca2+ signaling, and muscle degeneration. The gene discussed is TRPV2; the disease is cardiomyopathy.